Pazopanib better than sunitinib in advanced kidney cancer


Two oral targeted drugs -- Pazopanib (Votrient) and sunitinib (Sutent) -- approved for metastatic kidney cancer worked equally well, but one proved superior in tolerability, the safety profile and many measures of quality of life favored pazopanib.

"Tolerability is a big part of the equation when drugs work equally well," said Toni Choueiri, MD, director of the Kidney Cancer Center at Dana-Farber/Brigham and Women's Cancer Care (DF/BWCC). "If patients are going to live the same life span, why not use the one that's better tolerated?"

Choueiri, who is also an associate professor of medicine at Harvard Medical School, is senior author of the report of a phase 3 trial of 1,100 metastatic kidney cancer patients treated at multiple centers in 14 countries. Robert Motzer, MD, of Memorial Sloan-Kettering Cancer Center, is the first author.

The trial, sponsored by GlaxoSmithKline Pharmaceuticals, which manufactures pazopanib, compared the efficacy, safety and tolerability of pazopanib and sunitinib, two similar tyrosine kinase inhibitors that hinder cancer cell growth by disrupting several biological pathways. Both drugs target multiple cell-surface tyrosine kinase receptors, including receptors for vascular endothelial growth factor (VEGF), a protein that cancer cells co-opt to form new blood vessels to support tumor growth.

The Food and Drug Administration approved sunitinib in 2006 and pazopanib in 2009 to treat advanced kidney cancer, which is notoriously resistant to conventional chemotherapy. The drugs previously demonstrated improved progression-free survival compared to Interferon or placebo; the current trial tested them head-to-head.

The median time before the cancer progressed was comparable: 8.4 months for pazopanib and 9.5 months for sunitinib. Median overall survival was also similar 28.4 months for patients taking pazopanib and 29.3 months for sunitinib.

Pazopanib patients had a higher rate of liver enzyme abnormalities, in some cases leading to discontinuation of the drug. However, pazopanib patients had lower rates of blood cell abnormalities, hand and foot soreness, mouth sores, low thyroid activity, nausea, and fatigue.

Most important, pazopanib was rated superior to sunitinib on 11 or 14 measures of quality of life. In addition, pazopanib patients had fewer phone consultations with providers and visited emergency rooms less frequently a difference the researchers said is significant because it could influence cost-benefit comparisons.

The study was funded by GlaxoSmithKline Pharmaceuticals. The study's findings are reported in the New England Journal of Medicine.


(Anil Kumar -- sub-editor compiled and published Pazopanib better than sunitinib in advanced kidney cancer at HealthNewsTrack on August 23, 2013 sourced from Dana-Farber Cancer Institute - http://www.dfci.harvard.edu/)

Kidney cancer - recent articles and current news stories:

- Gene is mutated in 1 in 3 patients with kidney cancer

Most related articles:

- Pazopanib better than sunitinib in advanced kidney cancer
- Breast cancer drug Tykerb to be subsidised - 5.3
- Preventing kidney disease in diabetes may prolong life - 5.2
- Androgen deprivation therapy for prostate cancer may increase kidney injury risk - 4.5
- Depression increases kidney failure risk - 4.2

More related articles:

- Pazopanib, Sunitinib, Advanced kidney cancer, Votrient, Sutent, Metastatic kidney cancer, Quality of life, Kidney cancer
- Preventing kidney disease in diabetes may prolong life - 16.6
- Avastin bevacizumab approval revoked to treat breast cancer in US - 12.5
- Depression increases kidney failure risk - 12.5
- Breast cancer drug Tykerb to be subsidised - 12.2

Kidney cancer related articles:

- Preventing kidney disease in diabetes may prolong life - 5.2
- Depression increases kidney failure risk - 4.2
- An apple a day keeps kidney stones away - 3.6
- LifePort Kidney Transporter improves kidney transplant results - 3.6

Kidney cancer article/news source:

Read more health articles from Dana-Farber Cancer Institute and health articles from USA.

Kidney cancer - search related terms:

Advanced kidney cancer, Kidney cancer, Metastatic kidney cancer, Pazopanib, Quality of life, Sunitinib, Sutent, Votrient,
Mission
Health Newstrack is dedicated to serve recent and updated health & medical research, events/news, views/reviews to its subscribers and free access to general public, health & medical professionals, and other health seekers worldwide online with a user-friendly system. Track health news daily at Health Newstrack.
Subscribe: rss | email

Top sections:
Health (188)
Breast cancer (169)
Healthcare (134)
HIV (130)
Obesity (126)
Pregnancy (115)
Diabetes (102)
Swine Flu (97)
Prostate Cancer (86)
Heart disease (85)
Smoking (81)
Alzheimer's Disease (79)
Cancer (75)
Depression (61)
Autism (53)


Current news
Pazopanib shows better quality-of-life in advanced kidney cancer

What is Kidney cancer?
About Kidney cancer -- Renal cell carcinoma, also known by the eponym Grawitz tumor, is the most common form of kidney cancer arising from the renal tubule. It is the most common type of kidney cancer in adults. Initial therapy is with surgery. It is notoriously resistant to radiation therapy and chemotherapy, although some cases respond to immunotherapy.


List health news, Health organizations, Health news world, Glossary     Go to top

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information, and Health News Track is hon code accredited, verify here.
About us, Site map Privacy policy, Disclaimer
© 2015 HealthNewstrack.com
Health Newstrack - Track Health News Daily at HealthNewstrack.com. Our Newstrack on Health News provides latest health news, medical news, and health articles with recent health & medical updates.
1.26